India’s Supreme Court Dismisses Novartis’ Glivec Patent, Finding Bioavailability Alone Does Not Create New Product
This article was originally published in The Pink Sheet Daily
Executive Summary
The top court delivers a landmark judgment that threatens to deter future Big Pharma investments in India, but judges argue that Section 3(d) Of India Patent Act still allows incremental innovations to get intellectual property protection.